Depixus Wins SLAS Ignite Award for Transformative Molecular Interaction Technology


Depixus honored with SLAS2024 Ignite Award for its MAGNA™ technology

Depixus, an innovator in the field of interactomics, was recognized for their groundbreaking technology with the Society for Laboratory Automation and Screening (SLAS) Ignite Award. This award was presented at the society’s annual International Conference and Exhibition in Boston, MA. The Ignite Award recognizes companies that provide transformative technologies for life sciences research and was judged by a panel of experts based on innovation, marketing presence, messaging, impact, funding, and balanced leadership.

Depixus was one of 16 companies selected to participate in the SLAS2024 Innovation AveNEW program. Their MAGNA One™ instrument was shortlisted as a finalist after being showcased at the conference. This instrument is based on magnetic force spectroscopy and allows high-throughput analysis of dynamic biomolecular interactions. It is the first technology to provide direct, simultaneous, and real-time measurements from thousands of individual molecules. The MAGNA One™ instrument is particularly valuable for studying challenging targets such as RNA and protein-protein interactions, providing insights into disease mechanisms and accelerating the development of novel therapeutics.

Gordon Hamilton, CEO of Depixus expressed his excitement about winning the Ignite Award and thanked the other finalists for their competition. He emphasized the importance of this innovative technology to impact our understanding and treatment of diseases where new treatments are desperately needed. Steve Klose, Chief Commercial Officer of Depixus highlighted that this award coincided with the launch of their technology access program and commercial rollout of MAGNA One™ instrument. Klose expressed his excitement for researchers to use this new tool to transform their work in life sciences research.

For more information about Depixus’ MAGNA One™ instrument visit depixus.com

Leave a Reply